Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US. Characteristics, treatment patterns, and prognostic factors in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results